GlycoMimetics, Inc.

GlycoMimetics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. GlycoMimetics, Inc. is not a good value stock. GlycoMimetics, Inc. is not very popular among insiders. GlycoMimetics, Inc. is a mediocre stock to choose.

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discove...

News

StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC)

Ticker Report StockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC - Free Report) in a report issued on Wednesday. The brokerage issued a sell rating on the biotechnology company's stock. Several...\n more…

GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com

Ticker Report StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC - Free Report) in a report published on Tuesday. The firm issued a sell rating on the biotechnology company's stock. Several...\n more…

GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com

Zolmax Equities research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "sell" rating...\n more…

StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC)

Zolmax Research analysts at StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC - Get Free Report) in a research report issued to clients and investors on Monday. The firm set a "sell...\n more…

GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com

Ticker Report Equities research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC - Get Free Report) in a research report issued to clients and investors on Monday. The firm set...\n more…

GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com

Ticker Report StockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC - Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biotechnology...\n more…